Form 4: Centessa Pharmaceuticals Acquisition Complete

Centessa Pharmaceuticals plc's acquisition by Eli Lilly and Company has been finalized, with shareholders receiving cash and contingent value rights.

Summary

• Centessa Pharmaceuticals plc has been acquired by Eli Lilly and Company through a scheme of arrangement.
• The transaction, effective June 24, 2026, involved Eli Lilly's subsidiary, LDH XV Corporation, acquiring all outstanding ordinary shares.
• Shareholders are entitled to receive $38.00 in cash per ordinary share, without interest and less applicable withholding taxes.
• Additionally, shareholders will receive one non-transferable contingent value right (CVR) per ordinary share, with potential contingent payments of up to $9.00 per share based on specified milestones.
• All outstanding and unvested Restricted Share Units (RSUs) were fully vested and converted into the right to receive the cash consideration and a CVR.
• Similarly, all outstanding share options were cancelled and converted into the right to receive cash equal to the excess of the cash consideration over the exercise price, plus a CVR.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development for Centessa shareholders, as the acquisition provides a clear cash payout and potential for additional value through CVRs, reflecting a successful exit.

Positives

• Shareholders received a cash payment of $38.00 per ordinary share.
• Shareholders are eligible for potential additional payments of up to $9.00 per ordinary share through contingent value rights (CVRs).
• The acquisition provides a clear exit for shareholders and option holders.

Negatives

• The acquisition means Centessa Pharmaceuticals plc will no longer be a publicly traded entity.
• The contingent value of the CVRs is not guaranteed and depends on the achievement of specified milestones.

Risks

• The realization of contingent payments from the CVRs is dependent on Eli Lilly achieving specific, undisclosed milestones.
• There is a risk that the milestones for the CVRs may not be met, resulting in no additional payments beyond the initial cash consideration.

Future Outlook

The future outlook for Centessa Pharmaceuticals plc as an independent entity is concluded. The value for former shareholders and option holders will depend on the achievement of specific milestones related to the Contingent Value Rights (CVRs) issued by Eli Lilly and Company.

Management Comments

• The transfer of Ordinary Shares occurred automatically at the Effective Time pursuant to the Scheme of Arrangement, without any action by or discretion of the Reporting Person.
• At the Effective Time, holders of Ordinary Shares became entitled to receive (a) $38.00 in cash per Ordinary Share, without interest and less any applicable withholding taxes, and (b) one non-transferable contingent value right (a 'CVR') entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones.

Industry Context

StockSavvy.ai notes that this Form 4 filing confirms the completion of a significant acquisition in the pharmaceutical sector. Such transactions are common as larger companies like Eli Lilly seek to acquire innovative assets or pipeline candidates from smaller biopharmaceutical firms, often at a premium to market value, to bolster their portfolios.

Stakeholder Impact

• Shareholders: Receive $38.00 cash per share and a CVR with potential for up to $9.00 additional per share.
• Option Holders: Receive cash equal to the excess of the cash consideration over the exercise price, plus a CVR.
• RSU Holders: Receive $38.00 cash per share underlying the RSU and a CVR.
• Employees: Their roles and future employment will be determined by Eli Lilly and Company following the acquisition.
• Creditors: The acquisition terms do not explicitly detail the impact on creditors, but typically, the acquiring entity assumes liabilities or makes arrangements for them.

Next Steps

• Shareholders and former option/RSU holders will await the achievement of specified milestones to determine the payout of the Contingent Value Rights (CVRs).
• Eli Lilly and Company will integrate Centessa's assets and operations.

Key Dates

Keywords

Centessa Pharmaceuticals, Eli Lilly, Acquisition, Scheme of Arrangement, Form 4, Insider Trading, Share Options, RSUs, Contingent Value Rights, CNTA